Clinical trials · North Carolina
Cancer clinical trials in North Carolina
We’re tracking 617 recruiting cancer studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
Chapel Hill, North CarolinaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Asheboro, North CarolinaAges Any age - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Huntersville, North CarolinaAges 18 years+ - NCT06634381Recruiting
Fatigue in cancer survivors: A study to learn more
This study asks cancer survivors about their fatigue (tiredness, weakness, or exhaustion) to better understand it. It involves filling out questionnaires and maybe an interview. Your participation helps doctors learn how to support survivors like you.
Charlotte, North CarolinaAges 18 years+ - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Charlotte, North CarolinaAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Chapel Hill, North CarolinaAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Durham, North CarolinaAges 21 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Jacksonville, North CarolinaAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Clemmons, North CarolinaAges 18 years+ - NCT03769415Recruiting
Using tumor gene data to improve treatment in metastatic breast cancer
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
Raleigh, North CarolinaAges 18–99 - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Charlotte, North CarolinaAges 18 years+ - NCT05451004RecruitingPhase 3
SPECT-CT test to target neck radiation on one side
This study tests whether using a special scan (SPECT-CT) can guide radiation treatment to only the safer/needed side of the neck in people with a one-sided oropharyngeal cancer. It aims to keep cancer control while potentially reducing side effects from unnecessary radiation.
Chapel Hill, North CarolinaAges 18 years+ - NCT06205485RecruitingPhase 3
Chemotherapy and surgery vs chemoradiation for rectal cancer
This trial compares two approaches for early-stage rectal cancer: chemotherapy plus local surgery versus standard chemoradiotherapy. It aims to see if less intensive treatment can work just as well, reducing side effects.
Greenville, North CarolinaAges 18 years+ - NCT04333537RecruitingPhase 2/Phase 3
Sentinel node biopsy versus standard neck surgery for early mouth cancer
This trial compares two ways of checking whether early oral cavity squamous cell cancer has spread to neck lymph nodes. It tests whether sentinel lymph node biopsy can find spread as well as standard neck dissection, while potentially reducing more extensive surgery for some people.
Chapel Hill, North CarolinaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
Charlotte, North CarolinaAges 18 years+ - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Chapel Hill, North CarolinaAges 18 years+ - NCT04510597RecruitingPhase 3
Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Clinton, North CarolinaAges 18 years+ - NCT04743674Recruiting
Blood and urine tests to track cervical cancer after treatment
This study tests whether DNA found in blood and urine can help detect cervical cancer and monitor it after treatment. If you’re newly diagnosed, these minimally invasive samples may help doctors follow your disease more easily over time.
Chapel Hill, North CarolinaAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Charlotte, North CarolinaAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
Huntersville, North CarolinaAges 18 years+ - NCT05029999RecruitingPhase 1
Test drugs for HER2-negative advanced breast cancer
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
Chapel Hill, North CarolinaAges 18–99 - NCT05327686RecruitingPhase 2
Adding focused radiation to immunotherapy for kidney cancer
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Cary, North CarolinaAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Salisbury, North CarolinaAges 18 years+ - NCT05440929Recruiting
Testing a breast-cancer prognostic tool with U.S. clinicians
This study checks how acceptable, appropriate, and easy to use a metastatic breast-cancer “prognostic calculator” is for clinicians. It may help clinicians use the tool in real practice to support care decisions for people with metastatic breast cancer.
Chapel Hill, North CarolinaAges Any age
Cancer trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting cancer studies listed above.
- Levine Cancer Institute · 5 studies
- University of North Carolina at Chapel Hill · 5 studies
- UNC Lineberger Comprehensive Cancer Center · 4 studies
- Wake Forest University Health Sciences · 4 studies
- Duke University Medical Center · 3 studies
- Southeastern Medical Oncology Center · 3 studies
- Southeastern Medical Oncology Center-Clinton · 3 studies
- Southeastern Medical Oncology Center-Jacksonville · 3 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in North Carolina?
- Yes. We're currently tracking 617 recruiting cancer studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.